ArticleCurrent immunology reviews2019
Mucosal Vaccine Approaches for Prevention of HIV and SIV Transmission.
Article in Current immunology reviews, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Controlling timing and location in vaccines.Advanced drug delivery reviews · 2020Pooled it
- Intranasal Delivery of HIV/SIV Antigens with NE/AS01B Adjuvants Enhances Cellular Immunity and Reduces Viral Loads in SHIV-Challenged Macaques.bioRxiv : the preprint server for biology · 2026Article
- Sublingual and Buccal Delivery: A Historical and Scientific Prescriptive.Pharmaceutics · 2025Review
- Induction of Tier 2 HIV-Neutralizing IgA Antibodies in Rhesus Macaques Vaccinated with BG505.664 SOSIP.Vaccines · 2024Article
- Alcaligenes lipid A functions as a superior mucosal adjuvant to monophosphoryl lipid A via the recruitment and activation of CD11b+ dendritic cells in nasal tissue.International immunology · 2024Article
- The initial interplay between HIV and mucosal innate immunity.Frontiers in immunology · 2023Review
- Development of mucosal vaccine delivery: an overview on the mucosal vaccines and their adjuvants.Clinical and experimental vaccine research · 2022Review
- The unfulfilled potential of mucosal immunization.The Journal of allergy and clinical immunology · 2022Review
- Mucosal Delivery of HIV-1 Glycoprotein Vaccine Candidate Enabled by Short Carbon Nanotubes.Particle & particle systems characterization : measurement and description of particle properties and behavior in powders and other disperse systems · 2022Article
- Review
- Cooperation Between Systemic and Mucosal Antibodies Induced by Virosomal Vaccines Targeting HIV-1 Env: Protection of Indian Rhesus Macaques Against Low-Dose Intravaginal SHIV Challenges.Frontiers in immunology · 2022Article
- Designing spatial and temporal control of vaccine responses.Nature reviews. Materials · 2022Review
- Vaginal delivery of vaccines.Advanced drug delivery reviews · 2021Review
- Sublingual Immunization with Chimeric C1q/CD40 Ligand/HIV Virus-like Particles Induces Strong Mucosal Immune Responses against HIV.Vaccines · 2021Article
- The Role of Mucosal Immunity and Recombinant Probiotics in SARS-CoV2 Vaccine Development.Probiotics and antimicrobial proteins · 2021Review
- Review
- Virosome-based nanovaccines; a promising bioinspiration and biomimetic approach for preventing viral diseases: A review.International journal of biological macromolecules · 2021Review
- Effects of persistent modulation of intestinal microbiota on SIV/HIV vaccination in rhesus macaques.NPJ vaccines · 2021Article
- Flt3-L enhances trans-epithelial migration and antigen presentation of dendritic cells adoptively transferred to genital mucosa.Journal of controlled release : official journal of the Controlled Release Society · 2021Article
- Oral Vaccination Approaches for Anti-SHIV Immunity.Frontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Optimal protective immunity to HIV will likely require that plasma cells, memory B cells and memory T cells be stationed in mucosal tissues at portals of viral entry. Mucosal vaccine administration is more effective than parenteral vaccine delivery for this purpose. The challenge has been to achieve efficient vaccine uptake at mucosal surfaces, and to identify safe and effective adjuvants, especially for mucosally administered HIV envelope protein immunogens. Here, we discuss strategies used to deliver potential HIV vaccine candidates in the intestine, respiratory tract, and male and female genital tract of humans and nonhuman primates. We also review mucosal adjuvants, including Toll-like receptor agonists, which may adjuvant both mucosal humoral and cellular immune responses to HIV protein immunogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.